These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 16965187)

  • 41. Wayne Fenton's impact on industry.
    Breier A; Alphs L; Binneman B
    Schizophr Bull; 2007 Sep; 33(5):1154-5. PubMed ID: 17562696
    [No Abstract]   [Full Text] [Related]  

  • 42. Initiatives to promote the discovery of drugs to improve cognitive function in severe mental illness.
    Marder SR
    J Clin Psychiatry; 2006 Jul; 67(7):e03. PubMed ID: 17107228
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Symptom domains of schizophrenia: the role of atypical antipsychotic agents.
    Burton S
    J Psychopharmacol; 2006 Nov; 20(6 Suppl):6-19. PubMed ID: 17046984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Developing predictive animal models and establishing a preclinical trials network for assessing treatment effects on cognition in schizophrenia.
    Floresco SB; Geyer MA; Gold LH; Grace AA
    Schizophr Bull; 2005 Oct; 31(4):888-94. PubMed ID: 16079387
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The CATIE schizophrenia trial: results, impact, controversy.
    Manschreck TC; Boshes RA
    Harv Rev Psychiatry; 2007; 15(5):245-58. PubMed ID: 17924259
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Executive function in schizophrenia: what impact do antipsychotics have?
    O'Grada C; Dinan T
    Hum Psychopharmacol; 2007 Aug; 22(6):397-406. PubMed ID: 17579928
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacoeconomic factors related to the treatment of schizophrenia. Concluding discussion.
    J Clin Psychiatry; 1999; 60 Suppl 3():59-60. PubMed ID: 10073380
    [No Abstract]   [Full Text] [Related]  

  • 49. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee SH; Lee YH; Yang SJ; Yoon JS
    Hum Psychopharmacol; 2009 Oct; 24(7):565-73. PubMed ID: 19790174
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia.
    Friedman JI; Carpenter D; Lu J; Fan J; Tang CY; White L; Parrella M; Bowler S; Elbaz Z; Flanagan L; Harvey PD
    J Clin Psychopharmacol; 2008 Feb; 28(1):59-63. PubMed ID: 18204342
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Executive functioning component mechanisms and schizophrenia.
    Kerns JG; Nuechterlein KH; Braver TS; Barch DM
    Biol Psychiatry; 2008 Jul; 64(1):26-33. PubMed ID: 18549874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Developing methodologies for monitoring long-term safety of psychotropic medications in children: report on the NIMH conference, September 25, 2000.
    Greenhill LL; Vitiello B; Abikoff H; Levine J; March JS; Riddle MA; Capasso L; Cooper TB; Davies M; Fisher P; Findling RL; Fried J; Labellarte MJ; McCracken JT; McMahon D; Robinson J; Skrobala A; Scahill L; Varipatis E; Walkup JT; Zito JM
    J Am Acad Child Adolesc Psychiatry; 2003 Jun; 42(6):651-5. PubMed ID: 12921472
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Clinical Antipsychotic Trials of Intervention Effectiveness: what did we learn?
    Boyd MA
    Arch Psychiatr Nurs; 2008 Feb; 22(1):56-8. PubMed ID: 18207059
    [No Abstract]   [Full Text] [Related]  

  • 54. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment.
    Harvey PD; Keefe RS
    Am J Psychiatry; 2001 Feb; 158(2):176-84. PubMed ID: 11156796
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identifying cognitive mechanisms targeted for treatment development in schizophrenia: an overview of the first meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative.
    Carter CS; Barch DM; Buchanan RW; Bullmore E; Krystal JH; Cohen J; Geyer M; Green M; Nuechterlein KH; Robbins T; Silverstein S; Smith EE; Strauss M; Wykes T; Heinssen R
    Biol Psychiatry; 2008 Jul; 64(1):4-10. PubMed ID: 18466880
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.
    Buchanan RW; Davis M; Goff D; Green MF; Keefe RS; Leon AC; Nuechterlein KH; Laughren T; Levin R; Stover E; Fenton W; Marder SR
    Schizophr Bull; 2005 Jan; 31(1):5-19. PubMed ID: 15888422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Factors affecting outcome in schizophrenia and their relevance for psychopharmacological treatment.
    Altamura AC; Bobo WV; Meltzer HY
    Int Clin Psychopharmacol; 2007 Sep; 22(5):249-67. PubMed ID: 17690594
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Reducing dosage in maintenance treatment of schizophrenia. Review and prognosis.
    Schooler NR
    Br J Psychiatry Suppl; 1993 Dec; (22):58-65. PubMed ID: 7906525
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [The relationship between cognition and functional outcome in schizophrenia].
    Komlósi S; Czobor P; Bálint S; Bitter I
    Psychiatr Hung; 2008; 23(3):166-76. PubMed ID: 18956623
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.